Completion rates weren't a strong part of Blarca trial. Though I would note in regards to the 'survival bias' argument made by some critics in terms of the higher dropouts in main trial in dosed group (though in 30mg group the disparity was equal to Donanemabs ITT disparity), in the OLE the completion rates reversed with higher dropout in original placebo group.
OLE completion rates from start of OLE to finish
from week 48 to 144 (96 weeks) original Dosed completion = 58.22% original Placebo completion = 47%
From week 48 to 192 (144 weeks) - only Aus patients recorded this far I believe
original Dosed completion = 34.17 original Placebo completion = 30.3%
Therefore if you believed in the survival bias argument by some critics (that weaker patients drop out skewing the results to the positive for the cohorts with higher drop out) then the original placebo group should have done better in the OLE, however obv this didn't happen the groups moved further away from one another in both primary endpoints and eventually for ADL become stat sig different.
This is different from Lecanemab where after 3 years if anything it looks like the late start group was converging a bit on the early start group (arguably it should have been easier for early start group to stay ahead assuming drug works well as they'd been on in 18 months before other group starting taking it, vs Blarca 48 weeks before late start group)
Market Data 
Markets 
AI
